| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Chymotrypsin, Stool
Test Code11235X
CPT Codes
84311
Preferred Specimen
1 g random stool in a sterile leak-proof container
Patient Preparation
Patients receiving pancreatic enzymes should discontinue taking the enzymes at least 5 days before the collection of the stool sample
Minimum Volume
0.5 g
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Methodology
Enzymatic/Spectrophotometric
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Wed; Report available: 3-11 days
Clinical Significance
The diagnosis of chronic pancreatitis depends upon the demonstration of functional impairment of the pancreas. Impairment is determined by several means, two of which are:
1. Direct measurement of exocrine secretion into the duodenum after stimulation by a standard meal or after stimulation by intravenous secretin/pancreozymin.
2. The direct measurement of the activities of certain enzymes in feces. Chymotrypsin activity in stool, for example, has been shown to be lower than normal in patients with pancreatic exocrine insufficiency.
1. Direct measurement of exocrine secretion into the duodenum after stimulation by a standard meal or after stimulation by intravenous secretin/pancreozymin.
2. The direct measurement of the activities of certain enzymes in feces. Chymotrypsin activity in stool, for example, has been shown to be lower than normal in patients with pancreatic exocrine insufficiency.
